Brian Park, PharmD

KYV-101 is a novel, fully human anti-CD19 chimeric antigen receptor T-cell therapy.

Lynparza is a poly polymerase inhibitor.

Abrysvo is expected to be available in the third quarter of 2023.

A regulatory decision is expected on November 25, 2023.

A regulatory decision is expected on November 27, 2023.

Inpefa is expected to be available by the end of June 2023.

SI-6603 is administered via a single, direct intradiscal injection.

Milvexian is an investigational oral factor XIa inhibitor.

Yuflyma is expected to be available in July 2023.

Brixadi is supplied as prefilled single-dose syringes in weekly (8mg, 16mg, 24mg, 32mg) and monthly (64mg, 96mg, 128mg) doses.